These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35452324)

  • 21. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
    Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis.
    Lee YM; Lee SH; Kim TH; Park EJ; Park YA; Jang JS
    Cardiol J; 2022; 29(3):499-508. PubMed ID: 33140391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Future perspectives of the pharmacological management of diabetic dyslipidemia.
    Patti AM; Giglio RV; Papanas N; Rizzo M; Rizvi AA
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):129-143. PubMed ID: 30644763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 26. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asthma Exacerbations in Patients with Type 2 Diabetes and Asthma on Glucagon-like Peptide-1 Receptor Agonists.
    Foer D; Beeler PE; Cui J; Karlson EW; Bates DW; Cahill KN
    Am J Respir Crit Care Med; 2021 Apr; 203(7):831-840. PubMed ID: 33052715
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes.
    Dey AK; Groenendyk J; Mehta NN; Gourgari E
    Clin Cardiol; 2019 Mar; 42(3):406-412. PubMed ID: 30635924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The year in cardiovascular medicine 2021: diabetes and metabolic disorders.
    Cosentino F; Bhatt DL; Marx N; Verma S
    Eur Heart J; 2022 Jan; 43(4):263-270. PubMed ID: 34974614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020.
    Sherrill CH; Hwang AY
    Ann Pharmacother; 2024 Mar; 58(3):248-254. PubMed ID: 37323006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ; Aghar-Jaffar R; Shun-Shin MJ; Francis D; Oliver N; Meeran K
    JAMA; 2018 Apr; 319(15):1580-1591. PubMed ID: 29677303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
    Sarafidis P; Ferro CJ; Morales E; Ortiz A; Malyszko J; Hojs R; Khazim K; Ekart R; Valdivielso J; Fouque D; London GM; Massy Z; Ruggenenti P; Porrini E; Wiecek A; Zoccali C; Mallamaci F; Hornum M
    Nephrol Dial Transplant; 2019 Feb; 34(2):208-230. PubMed ID: 30753708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.
    Uneda K; Kawai Y; Yamada T; Kinguchi S; Azushima K; Kanaoka T; Toya Y; Wakui H; Tamura K
    Sci Rep; 2021 May; 11(1):10166. PubMed ID: 33986377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.
    Luna-Marco C; Iannantuoni F; Hermo-Argibay A; Devos D; Salazar JD; Víctor VM; Rovira-Llopis S
    Free Radic Biol Med; 2024 Mar; 213():19-35. PubMed ID: 38220031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
    Bailey CJ
    Lancet Diabetes Endocrinol; 2020 Feb; 8(2):97-99. PubMed ID: 31843565
    [No Abstract]   [Full Text] [Related]  

  • 39. JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk.
    Wyne KL; Litwin SE; Cusi K; Guyton JR
    J Clin Lipidol; 2022; 16(2):115-127. PubMed ID: 35430025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.